Incidence and Predictors of QTC Prolongation Among Drug-Resistant Tuberculosis Patients Receiving Bedaquiline-Based TB Regimens in Uganda: A Countrywide Retrospective Cohort Study
Marble Nasasira, Kevin Ouma Ojiambo, Daniel Iraguha, Joseph Baruch Baluku · 2026
Read Incidence and Predictors of QTC Prolongation Among Drug-Resistant Tuberculosis Patients Receiving Bedaquiline-Based TB Regimens in Uganda: A Countrywide Retrospective Cohort Study by Marble Nasasira, Kevin Ouma Ojiambo, Daniel Iraguha, Joseph Baruch Baluku (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13678221.txt.
Description
Marble Nasasira and co-authors published this tuberculosis study in 2026 from Uganda. Bedaquiline is a key drug against drug-resistant TB, but it can stretch the heart's QTc interval, a rhythm risk. The team read records from fourteen treatment sites, spanning 2017 to 2022, for 532 patients. They counted new cases of the stretch and hunted its predictors.
The rate came to twelve new cases per thousand person-months. Low body mass raised the risk, so thin patients need the closest heart tracing watch. Cure rates matched between those with and without the stretch, near seventy percent in both. Most patients were men, and a third also had HIV. The authors urge monthly heart tracings as the drug's use grows, with extra care for the underweight.
Catalog record
| CREATOR | Marble Nasasira, Kevin Ouma Ojiambo, Daniel Iraguha, Joseph Baruch Baluku |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 27 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |